MX2015001194A - Composiciones inhibidoras de eflujo y metodos de tratamiento que usan las mismas. - Google Patents

Composiciones inhibidoras de eflujo y metodos de tratamiento que usan las mismas.

Info

Publication number
MX2015001194A
MX2015001194A MX2015001194A MX2015001194A MX2015001194A MX 2015001194 A MX2015001194 A MX 2015001194A MX 2015001194 A MX2015001194 A MX 2015001194A MX 2015001194 A MX2015001194 A MX 2015001194A MX 2015001194 A MX2015001194 A MX 2015001194A
Authority
MX
Mexico
Prior art keywords
methods
inhibitor compositions
effluz
treatment
same
Prior art date
Application number
MX2015001194A
Other languages
English (en)
Inventor
Antonius Martinus Gustave Bunt
Olaf Van Tellingen
Original Assignee
Izumi Technology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Izumi Technology Llc filed Critical Izumi Technology Llc
Publication of MX2015001194A publication Critical patent/MX2015001194A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a las composiciones y los métodos del inhibidor del eflujo para usar estos agentes para el tratamiento de padecimientos donde la actividad de las proteínas portadoras del eflujo (por ejemplo, la proteína resistente al cáncer de mama (BCRP) y P-glicoproteína (P-GP)) inhibe la administración efectiva de un agente terapéutico a un tejido objetivo (por ejemplo, al cerebro, a la médula espinal, los nervios, el líquido cefalorraquídeo, los testículos, los ojos, la retina, el oído interno, la placenta, la glándula mamaria, el hígado, el tracto biliar, los intestinos, el pulmón, el riñón, los intestinos, las células hematopoyiéticas, y/o células madre).
MX2015001194A 2012-07-27 2013-07-26 Composiciones inhibidoras de eflujo y metodos de tratamiento que usan las mismas. MX2015001194A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261676689P 2012-07-27 2012-07-27
PCT/US2013/052402 WO2014018932A2 (en) 2012-07-27 2013-07-26 Effluz inhibitor compositions and methods of treatment using the same

Publications (1)

Publication Number Publication Date
MX2015001194A true MX2015001194A (es) 2015-11-23

Family

ID=48917738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001194A MX2015001194A (es) 2012-07-27 2013-07-26 Composiciones inhibidoras de eflujo y metodos de tratamiento que usan las mismas.

Country Status (12)

Country Link
US (4) US20140235631A1 (es)
EP (1) EP2877159B8 (es)
JP (1) JP6464084B2 (es)
CN (1) CN104736144B (es)
AU (1) AU2013295549B2 (es)
BR (1) BR112015001838B1 (es)
CA (1) CA2880236C (es)
ES (1) ES2656091T3 (es)
HK (1) HK1210957A1 (es)
IN (1) IN2015MN00408A (es)
MX (1) MX2015001194A (es)
WO (1) WO2014018932A2 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US11147809B2 (en) 2010-08-27 2021-10-19 Neonc Technologies, Inc. Methods of treating neurofibromatosis with perillyl alcohol
WO2018005994A1 (en) * 2016-07-01 2018-01-04 Neonc Technologies, Inc. Methods of treating neurofibromatosis with perillyl alcohol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2897620B1 (en) 2012-09-21 2020-07-22 Intensity Therapeutics, Inc Method of treating cancer
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150095055A1 (en) * 2013-09-30 2015-04-02 Horizon Pharma Usa, Inc. Methods for processing a prescription drug request
CA2933464A1 (en) * 2013-12-09 2015-06-18 Thomas Jefferson University Use of abc drug efflux inhibitors in combination with anti-neurodegenerative drugs in the treatment of neurodegenerative disorders
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
CN104352632B (zh) * 2014-11-12 2017-11-24 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为肝转运体抑制剂的应用
CN107635563A (zh) * 2014-11-17 2018-01-26 维多利亚联结有限公司 抗菌化合物
US20170360791A1 (en) * 2014-12-04 2017-12-21 Astex Pharmaceuticals, Inc. Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
CN104784179A (zh) * 2015-04-01 2015-07-22 重庆理工大学 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物
KR101778004B1 (ko) * 2015-06-22 2017-09-15 (주) 에빅스젠 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
GB201516905D0 (en) * 2015-09-24 2015-11-11 Stratified Medical Ltd Treatment of Neurodegenerative diseases
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US11110172B2 (en) 2016-04-08 2021-09-07 Imam Abdulrahman Bin Faisal University Method for treating multiloculated hydrocephalus by administering an anti-IL6 receptor antibody
WO2017192942A1 (en) * 2016-05-06 2017-11-09 THE USA, as representd by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES Methods for improving drug delivery across a p-glycoprotein expressing barrier
CN107397721B (zh) * 2016-05-18 2019-01-22 中国医学科学院基础医学研究所 含有布比卡因的药物组合物及其制备方法和用途
US10864280B2 (en) 2016-06-09 2020-12-15 Der-Yang Tien Nanodroplet compositions for the efficient delivery of anti-cancer agents
CA3027368A1 (en) * 2016-06-13 2017-12-21 Ascendia Pharmaceuticals, Llc Parenteral sustained-release delivery of carvedilol disperse systems
EP3478364A4 (en) * 2016-07-01 2019-10-23 Dignity Health DIAGNOSIS OR PREDICTOR OF RECURRENT-RESTRICTED MULTIPLE SCLEROSIS
US10912777B2 (en) * 2016-12-22 2021-02-09 Academia Sinica Dipyridamole for use in treating SLC29A2 nuclear-expressing cancer
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018204829A1 (en) * 2017-05-04 2018-11-08 University Of Maryland, Baltimore Methods for preventing neural tube defects in diabetic pregnancy
MX2019014298A (es) * 2017-06-09 2020-02-03 Exelixis Inc Formas de dosificacion liquida para tratar el cancer.
WO2019028298A1 (en) * 2017-08-03 2019-02-07 Truong Daniel Dung USE OF TYROSINE KINASE ABELSON INHIBITOR IN THE TREATMENT OF MULTISYSTEMIZED ATROPHY
US20200390717A1 (en) * 2017-11-21 2020-12-17 University Of Iowa Research Foundation Synthetically lethal nanoparticles for treatment of cancers
ES2943933T3 (es) 2018-01-12 2023-06-16 Orion Corp Colirios de palonosetrón para el tratamiento o la prevención de náuseas y vómitos
CA3093985A1 (en) * 2018-03-21 2019-09-26 Izumi Technology, Llc Deuterated analogs of elacridar
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
CN108484751B (zh) * 2018-04-19 2020-06-23 西南大学 川陈皮素抗原及其制备方法与应用
CN109111533B (zh) * 2018-05-10 2020-05-08 上海交通大学 硫酸肝素与fk506共轭物酶化学合成以及应用
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
CN108670950B (zh) * 2018-06-29 2020-10-02 深圳海王医药科技研究院有限公司 一种不含有机溶剂的虎杖苷药物组合物及其制备方法
CN108808030B (zh) * 2018-07-03 2023-08-08 重庆大学 基于b-z振荡反应的脉冲电池设计
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
TWI816881B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 用於治療三陰性乳癌之組合療法
CN111617258A (zh) * 2019-02-28 2020-09-04 江苏恒瑞医药股份有限公司 一种制备阿比特龙或其衍生物药物组合物的方法及其应用
CN110498784B (zh) * 2019-05-20 2022-06-14 广东克冠达医药科技有限公司 一类川陈皮素衍生物或其药学上可接受的盐及其制备方法和应用
CN111296417B (zh) * 2020-04-01 2021-04-20 广东省农业科学院植物保护研究所 一种星·甲维悬浮剂及其制备方法与应用
WO2022020114A2 (en) * 2020-07-10 2022-01-27 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
WO2022007878A1 (zh) * 2020-07-10 2022-01-13 长庚医疗财团法人林口长庚纪念医院 β-1肾上腺素受体拮抗剂用于制备减少表皮生长因子受体抑制剂诱导的上皮细胞损伤以及抑制癌细胞的组合物的用途
CN111840255B (zh) * 2020-07-31 2022-03-01 北京丰帆生物医药科技有限公司 一种维拉帕米温敏缓释制剂及其制备方法和应用
KR102444571B1 (ko) * 2020-11-18 2022-09-19 주식회사태준제약 세티리진 및 토코페솔란을 포함하는 안과용 조성물
CN113384702A (zh) * 2021-05-20 2021-09-14 温州医科大学附属第一医院 H1组胺受体拮抗剂在制备治疗神经胶质瘤的药物中的应用
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品
TW202423434A (zh) * 2022-10-07 2024-06-16 瑞士商歐庫利斯營運股份有限公司 mTOR抑制劑的點眼劑微懸液
CN115779089A (zh) * 2022-11-28 2023-03-14 中国医学科学院肿瘤医院 用于治疗或改善雄性癌症及抑制其细胞系的药物的相关应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CZ302788B6 (cs) 1999-04-15 2011-11-09 Bristol-Myers Squibb Company ´N-(2-Chlor-6-methylfenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolkarboxamid, jeho použití a farmaceutický prostredek s jeho obsahem
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
NZ525254A (en) 2000-10-27 2006-02-24 Novartis Ag Treatment of gastrointestinal stromal tumors
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1896831B1 (en) * 2005-06-27 2013-04-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES A spatially selective, fixed-optics multicolor fluorescence detection system for a multichannel microfluidic device, and method for detection
US20070053869A1 (en) * 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
DE102006013531A1 (de) * 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
JP2010510988A (ja) * 2006-11-28 2010-04-08 マリナス ファーマシューティカルズ ナノ粒子製剤とその製造方法およびその利用
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer

Also Published As

Publication number Publication date
WO2014018932A2 (en) 2014-01-30
AU2013295549A1 (en) 2015-03-19
US20200405683A1 (en) 2020-12-31
HK1210957A1 (en) 2016-05-13
EP2877159A2 (en) 2015-06-03
CA2880236A1 (en) 2014-01-30
JP6464084B2 (ja) 2019-02-06
JP2015523400A (ja) 2015-08-13
IN2015MN00408A (es) 2015-09-04
ES2656091T3 (es) 2018-02-23
WO2014018932A8 (en) 2014-12-31
BR112015001838B1 (pt) 2022-10-25
CA2880236C (en) 2022-09-13
AU2013295549B2 (en) 2018-04-19
EP2877159B8 (en) 2018-02-14
US20140235631A1 (en) 2014-08-21
US20190167630A1 (en) 2019-06-06
EP2877159B1 (en) 2017-11-08
CN104736144A (zh) 2015-06-24
CN104736144B (zh) 2019-02-01
WO2014018932A3 (en) 2014-03-20
BR112015001838A2 (pt) 2017-07-04
US20220133679A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
MX2015001194A (es) Composiciones inhibidoras de eflujo y metodos de tratamiento que usan las mismas.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
IL275754A (en) Compounds, compositions, and methods for treating diseases involving infected acidic or hypoxic tissues
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
PH12014501604A1 (en) Polypeptides binding to human complement c5
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
BR112013000433A2 (pt) diagnóstico e tratamento de câncer de mama
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
MX2015017853A (es) Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso.
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EP4124346A3 (en) Compositions and methods for treating diseases
MY187513A (en) Lectin-like oxidized ldl receptor 1 antibodies and methods of use
IL251349A0 (en) Routing of melanocytes to deliver medical or diagnostic agents using nanocage proteins
HK1232242A1 (zh) 用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物
MX2018002932A (es) Sintesis y composicion de agentes terapeuticos fotodinamicos para el tratamiento dirigido del cancer.
MX2017011600A (es) Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: IZUMI TECHNOLOGY, LLC.